证券代码：002793 证券简称：罗欣药业 公告编号：2025-077 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 公司名称：罗欣安若维他药业（成都）有限公司 公司类型：有限责任公司（外商投资、非独资） 成立日期：2019 年 3 月 25 日 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司罗欣安若维他药业（成都）有限公司（以下简称 "罗安公司"）人民币 2,000 万元银行授信额度提供担保。公司分别于 2025 年 8 月 1 日、2025 年 8 月 18 日召开第五届董事会第二十七次会议、第五届监事会第 二十三次会议及 2025 年第四次临时股东大会，审议通过了《关于为控股子公司 提供担保的议案》。具体内容详见 ...

Core Viewpoint - The company has announced a guarantee for its subsidiary, Luo Xin An Ruo Wei Ta Pharmaceutical (Chengdu) Co., Ltd., involving a bank credit limit of 20 million yuan, which has been approved and is now in progress [1] Group 1: Guarantee Details - The company signed a guarantee contract with Agricultural Commercial Bank, providing a joint liability guarantee for 10 million yuan of debt for Luo An Company, which does not require further review [1] - After this guarantee, the total guarantee balance for the company towards Luo An Company reaches 10 million yuan, with an available guarantee limit of another 10 million yuan [1] Group 2: Financial Health and Risk Assessment - Luo An Company is operating normally and has good creditworthiness, indicating a low risk associated with the guarantee [1] - The total guarantee amount for the company and its subsidiaries is 241.2 million yuan, with an external guarantee balance of 111.74 million yuan, and there are no overdue or bad guarantee situations [1] - The board of directors believes that the guarantee risk is controllable and aligns with the overall interests of the company [1]

Group 1 - The core point of the article is the resignation of Chen Xian as the financial head of Luoxin Pharmaceutical due to job relocation, and the appointment of Wu Yongsheng as the new financial head [1] - For the first half of 2025, Luoxin Pharmaceutical's revenue composition is as follows: pharmaceutical industry accounts for 88.11%, pharmaceutical commerce accounts for 10.1%, and other businesses account for 1.79% [1] - As of the report date, Luoxin Pharmaceutical has a market capitalization of 6.2 billion [1] Group 2 - The article also mentions similar appointments in other companies, such as the hiring of Zhang Ganlin as the financial head of Libet and Gu Li as the financial head of Xinyin Electronics [1] - Additionally, it notes the appointment of Bai Lin as the financial head of Lianrui New Materials [1]

（文章来源：证券日报） 证券日报网讯 9月8日晚间，罗欣药业发布公告称，公司董事会同意聘任武永生先生为公司财务负责 人。 ...

每经AI快讯，罗欣药业（SZ 002793，收盘价：5.69元）9月8日晚间发布公告称，罗欣药业集团股份有 限公司于2025年9月5日收到陈娴女士递交的书面辞职报告。因工作调动原因，陈娴女士申请辞去公司财 务负责人职务，将担任公司创新运营管理办公室副主任。因公司经营发展需要，经公司总经理提名，董 事会提名委员会、审计委员会审查，董事会同意聘任武永生先生为公司财务负责人。 （记者 王晓波） 截至发稿，罗欣药业市值为62亿元。 每经头条（nbdtoutiao）——"中国真正实现了弯道超车"！从美国回来14年，陈智胜亲历中国创新药大 爆发：以前跨国药企不太信任中国数据，但现在不同了 2025年1至6月份，罗欣药业的营业收入构成为：医药工业占比88.11%，医药商业占比10.1%，其他业务 占比1.79%。 ...

罗欣药业集团股份有限公司 关于财务负责人辞职及聘任财务负责人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002793 证券简称：罗欣药业 公告编号：2025-076 公司于 2025 年 9 月 8 日召开第五届董事会第二十九次会议，审议通过了《关 于聘任财务负责人的议案》。因公司经营发展需要，经公司总经理提名，董事会 提名委员会、审计委员会审查，董事会同意聘任武永生先生为公司财务负责人（简 历附后），任期自董事会审议通过之日起至第五届董事会届满之日止。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 9 月 8 日 1 附件：个人简历 一、财务负责人辞职情况 罗欣药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 5 日收到 陈娴女士递交的书面辞职报告。因工作调动原因，陈娴女士申请辞去公司财务负 责人职务，辞职后，将担任公司创新运营管理办公室副主任。截至本公告披露日， 陈娴女士未持有公司股份。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等有关规定，陈娴女士的辞职报告自送达公司董 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002793 股票简称：罗欣药业 公告编号：2025-075 罗欣药业集团股份有限公司 第五届董事会第二十九次会议决议公告 三、备查文件 1、董事会提名委员会会议决议。 1 2、董事会审计委员会会议决议。 特此公告。 2025 年 9 月 8 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届董事会第二十九次会议在山东省临沂高新技术产业开发区罗七路管理中心三 楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合 的方式召开。会议通知已于 2025 年 9 月 5 日以电话、专人送达、电子邮件等方 式发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、董事会秘书 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》等法律法规、规范性文件和《罗欣药业集团股份有限公司 章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于聘任财务负责人的议案》 陈娴女士因工作调动原因申请辞去公司财务负责人的职 ...

| 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 12.59亿 | 10.77亿 | -14.45% | | 归母浄利润（元） | -8870.99万 | 1769.5万 | 119.95% | | 扣非净利润(元) | -1.08亿 | 230.07万 | 102.14% | | 货币资金(元) | 8.98亿 | 2666E | -56.21% | | 应收账款(元) | 4.46亿 | 4.01亿 | -10.12% | | 有息负债(元) | 19.7亿 | 13.77 亿 | -30.10% | | 手利率 | 40.20% | 50.16% | 24.76% | | 净利率 | -9.64% | 2.04% | 121.18% | | 三费占营收比 | 47.50% | 47.24% | -0.54% | | 每股净资产 (元) | 2.1 | 1.3 | -38.12% | | 每股收益(元) | -0.08 | 0.02 | 125.00% | | 每股经营性现金流(元) | -0.13 | 0.2 ...

Core Viewpoint - The company has made significant changes in its capital structure and asset management, including capital increase in a subsidiary and the transfer of equity stakes in another subsidiary, which may impact its financial performance and consolidation scope [5][10]. Group 1: Company Overview - The company did not distribute cash dividends or issue new shares during the reporting period [3]. - The company’s controlling shareholder and actual controller did not change during the reporting period [5]. Group 2: Capital Increase and Related Transactions - The company approved a capital increase of RMB 12 million in its subsidiary, Beijing Health, raising its registered capital from RMB 23.36 million to RMB 35.36 million, increasing the company's ownership from 71.16% to 80.95% [5][6]. - The capital increase was completed with the necessary registration changes [6]. Group 3: Equity Transfer Progress - The company completed the transfer of 70% equity in its subsidiary, Shandong Luoxin Modern Logistics, to a related party, receiving RMB 207.48 million as the first installment of the transfer payment [7][8]. - The performance commitment for the transferred equity includes revenue and net profit targets, with the first-year performance completion rate at 95.76% [9]. Group 4: Public Sale of Subsidiary Equity - The company plans to publicly sell 100% equity of its wholly-owned subsidiary, Lekang Pharmaceutical, through a public listing, but has faced challenges in finding interested buyers [10].

Financial Performance - The company's total revenue for the first half of 2025 was 1.077 billion yuan, a decrease of 182 million yuan compared to the same period last year, representing a year-on-year decline of 14.45% [1] - The net profit attributable to shareholders was 17.695 million yuan, ranking 86th among disclosed peers [1] - The net cash inflow from operating activities was 218 million yuan [1] Financial Ratios - The latest debt-to-asset ratio was 61.94%, ranking 116th among disclosed peers, an increase of 6.71 percentage points compared to the same period last year [3] - The latest gross profit margin was 50.16% [3] - The return on equity (ROE) was 1.25%, ranking 85th among disclosed peers [3] Earnings and Turnover - The diluted earnings per share were 0.02 yuan, ranking 89th among disclosed peers [4] - The total asset turnover ratio was 0.26 times [4] - The inventory turnover ratio was 1.24 times, a decrease of 0.30 times compared to the same period last year, representing a year-on-year decline of 19.54% [4] Shareholder Structure - The number of shareholders was 36,500, with the top ten shareholders holding 558 million shares, accounting for 51.30% of the total share capital [4] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., held 21.79% of the shares [4]